AnlongBio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$14.2M
- Investors
-
16
AnlongBio General Information
Description
Developer of gene therapy technology intended to provide affordable and innovative treatments to patients. The company is mainly engaged in gene therapy for wet macular degeneration (wAMD) and AAV vector screening, enabling patients to obtain more effective gene therapy.
Contact Information
Website
www.anlongbio.comCorporate Office
- 5th Floor, North Building, Zhongguancun Medical Engineering Health Industry Base
- Number 10 Anxiang Street, Shunyi District
- Beijing, 101318
- China
Corporate Office
- 5th Floor, North Building, Zhongguancun Medical Engineering Health Industry Base
- Number 10 Anxiang Street, Shunyi District
- Beijing, 101318
- China
AnlongBio Timeline
AnlongBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B1) | 07-Jan-2026 | $14.2M | Completed | Generating Revenue | ||
| 7. Later Stage VC (Series B) | Completed | Generating Revenue | ||||
| 6. Secondary Transaction - Private | 26-Dec-2023 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A1) | 26-Dec-2023 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A) | 09-Jun-2021 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC | 06-Jan-2021 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Private | 06-Jan-2021 | $10M | Completed | Generating Revenue | ||
| 1. Seed Round | 08-Jul-2020 | $10M | $10M | Completed | Startup |
AnlongBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AnlongBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AnlongBio Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beijing Shunxi Private Equity Fund Management | Growth/Expansion | Minority | ||
| Beijing State-owned Capital Operation and Management | Government | Minority | ||
| Beijing Shunyi Technology Innovation | Government | Minority | ||
| Hangzhou Tailong Venture Capital Partnership | Growth/Expansion | Minority | ||
| Shunchuang Industry Venture Capital | Growth/Expansion | Minority |
AnlongBio FAQs
-
When was AnlongBio founded?
AnlongBio was founded in 2019.
-
Where is AnlongBio headquartered?
AnlongBio is headquartered in Beijing, China.
-
What is the size of AnlongBio?
AnlongBio has 4 total employees.
-
What industry is AnlongBio in?
AnlongBio’s primary industry is Drug Discovery.
-
Is AnlongBio a private or public company?
AnlongBio is a Private company.
-
What is AnlongBio’s current revenue?
The current revenue for AnlongBio is .
-
How much funding has AnlongBio raised over time?
AnlongBio has raised $54.2M.
-
Who are AnlongBio’s investors?
Beijing Shunxi Private Equity Fund Management, Beijing State-owned Capital Operation and Management, Beijing Shunyi Technology Innovation, Hangzhou Tailong Venture Capital Partnership, and Shunchuang Industry Venture Capital are 5 of 16 investors who have invested in AnlongBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
